AXL表达与乳腺癌预后及临床病理特征关系的Meta分析

目的 探讨受体酪氨酸激酶AXL蛋白的表达对乳腺癌患者预后及临床病理特征的意义。方法 在中国知网(CNKI)、万方医学网(Wanfang Data)、 Cochrane Library、Embase、PubMed和Medline数据库中,搜索国内外公开发表的有关AXL与乳腺癌预后关系的文献,检索时限均为从建库至2019年10月。2位研究者按纳入和排除标准独立筛选文献、提取资料和评价纳入研究的偏倚风险,并进行Meta分析。结果 共纳入7篇文献,包括933例乳腺癌患者。AXL高表达组的乳腺癌患者总生存期(overall survival,OS)明显低于低表达组(HR=2.36,95%CI 1.60~3.46,P<0.000 1),但其表达在无复发生存期(relapse free survival,RFS)和无疾病生存期(disease free survival,DFS)中差异无统计学意义,且与乳腺癌的年龄、临床分期、组织分级、淋巴结转移及受体表达的相关性分析无统计学意义。结论 AXL的阳性表达与乳腺癌患者预后不良有关,是乳腺癌个体化治疗的潜在分子标志物。

Prognostic and clinicopathological significance of AXL expression for breast cancer:a Meta-analysis

Objective To evaluate the prognostic and clinicopathological significance of AXL expression in breast cancer tissues by meta-analysis. Methods Such databases as CNKI, Wanfang Data, Cochrane Library, Embase, PubMed and Medline were searched for the studies on the prognostic value of AXL expression in breast cancer from inception to October 2019. Two researchers independently screened eligible literature, extracted data and evaluate the risk of bias of included studies to analyze the data. Results Seven studies involving 933 patients were included. It was shown that,the higher AXL expression group had a shorter overall survival than that of the lower AXL expression group(HR=2.36, 95%CI 1.60-3.46, P<0.000 1). However,there was no significant difference between two group in relapse free survival and disease free survival. It was shown that the expression of AXL was not associated with age, clinical stages, histologic grade, lymph node metastasis or receptor expression. Conclusion The meta-analysis suggests that AXL positive expression is associated with worse survival in patients. It will be a protential molecular marker for individualized treatment of breast cancer.